NASDAQ: HSCSHeart Test Laboratories Inc Stock
$1.11+0.10 (+9.9%)
Updated Mar 17, 2023
HSCS Price
$1.11
Fair Value Price
N/A
Market Cap
$10.81M
52 Week Low
$0.71
52 Week High
$6.00
P/E
-0.87x
P/B
-41.92x
P/S
1,896.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.30k
Earnings
-$6.78M
Gross Margin
56.2%
Operating Margin
-69,779.71%
Profit Margin
-72,858%
Debt to Equity
-14.49
Operating Cash Flow
-$5M
Beta
-0.25
Next Earnings
Mar 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A
HSCS Overview
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Zen Score
–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HSCS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HSCS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HSCS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
HSCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more HSCS due diligence checks available for Premium users.
Be the first to know about important HSCS news, forecast changes, insider trades & much more!
HSCS News
Valuation
HSCS fair value
Fair Value of HSCS stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
$1.19
Undervalued by
6.47%
HSCS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HSCS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.87x
Industry
93.94x
Market
21.81x
HSCS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-41.92x
Industry
3.75x
HSCS's financial health
Profit margin
Revenue
$2.0k
Net Income
-$1.3M
Profit Margin
-68,826.4%
HSCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HSCS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.5M
Liabilities
$3.7M
Debt to equity
-14.49
HSCS's short-term assets ($2.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSCS's short-term assets ($2.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSCS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HSCS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
-$3.5k
Financing
-$121.5k
HSCS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HSCS vs Medical Device Stocks
Heart Test Laboratories Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.